High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Detalles Bibliográficos
Autores principales: Decroo, Tom, de Jong, Bouke C., Piubello, Alberto, Souleymane, Mahamadou Bassirou, Lynen, Lutgarde, Van Deun, Armand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301730/
https://www.ncbi.nlm.nih.gov/pubmed/32130864
http://dx.doi.org/10.1164/rccm.202001-0201LE
_version_ 1783547746600353792
author Decroo, Tom
de Jong, Bouke C.
Piubello, Alberto
Souleymane, Mahamadou Bassirou
Lynen, Lutgarde
Van Deun, Armand
author_facet Decroo, Tom
de Jong, Bouke C.
Piubello, Alberto
Souleymane, Mahamadou Bassirou
Lynen, Lutgarde
Van Deun, Armand
author_sort Decroo, Tom
collection PubMed
description
format Online
Article
Text
id pubmed-7301730
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-73017302020-06-18 High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis Decroo, Tom de Jong, Bouke C. Piubello, Alberto Souleymane, Mahamadou Bassirou Lynen, Lutgarde Van Deun, Armand Am J Respir Crit Care Med Correspondence American Thoracic Society 2020-06-15 2020-06-15 /pmc/articles/PMC7301730/ /pubmed/32130864 http://dx.doi.org/10.1164/rccm.202001-0201LE Text en Copyright © 2020 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).
spellingShingle Correspondence
Decroo, Tom
de Jong, Bouke C.
Piubello, Alberto
Souleymane, Mahamadou Bassirou
Lynen, Lutgarde
Van Deun, Armand
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_full High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_fullStr High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_full_unstemmed High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_short High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_sort high-dose first-line treatment regimen for recurrent rifampicin-susceptible tuberculosis
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301730/
https://www.ncbi.nlm.nih.gov/pubmed/32130864
http://dx.doi.org/10.1164/rccm.202001-0201LE
work_keys_str_mv AT decrootom highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT dejongboukec highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT piubelloalberto highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT souleymanemahamadoubassirou highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT lynenlutgarde highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT vandeunarmand highdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis

Ejemplares similares